UCLA began enrolling patients with favorable intermediate risk prostate cancer for a new trial using the Avenda Health Focal Laser Ablation System (NCT04305925 ). This new technology is an office-based therapy that requires only local anesthesia and is designed to preserve sexual and urinary function.
